AZD7594

InvivoChem Cat #:V4246CAS #:1196509-60-0Purity >=98%

Description: AZD7594 (also known as AZ13189620) is a novel, potent selective nonsteroidal indazole ether-based glucocorticoid receptor modulators (SGRMs) with an IC50 of 0.9 nM. AZD-7594 is an inhaled selective glucocorticoid receptor (GCCR) modulator for the inhaled treatment of respiratory diseases. AZD7594 demonstrated an improved therapeutic ratio over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of lung edema, indicating potential for once-daily treatment. AZD-7594 is currently in phase II clinical trials by AstraZeneca for the treatment of mild to moderate asthma. It is also in phase I clinical trials for the treatment of chronic obstructive pulmonary disorder (COPD).

Description:

References: J Med Chem. 2017 Oct 26; 60(20):8591-8605.

References:

-20C for 3 years in powder form

Synonym: AZ13189620; AZ-13189620; AZ 13189620; AZD-7594; AZD 7594; AZD7594;
IUPAC/Chemical Name: 3-(5-((1R, 2S)-2-(2, 2-difluoropropanamido)-1-(2, 3-dihydrobenzo[b][1, 4]dioxin-6-yl)propoxy)-1H-indazol-1-yl)-N-(tetrahydrofuran-3-yl)benzamide
InChi Key: ZZWJKLGCDHYVMB-QMQODZDESA-N
InChi Code: InChI=1S/C32H32F2N4O6/c1-19(36-31(40)32(2, 33)34)29(20-6-9-27-28(16-20)43-13-12-42-27)44-25-7-8-26-22(15-25)17-35-38(26)24-5-3-4-21(14-24)30(39)37-23-10-11-41-18-23/h3-9, 14-17, 19, 23, 29H, 10-13, 18H2, 1-2H3, (H, 36, 40)(H, 37, 39)/t19-, 23?, 29-/m0/s1
SMILES Code: O=C(NC1COCC1)C2=CC=CC(N3N=CC4=C3C=CC(O[CH](C5=CC=C(OCCO6)C6=C5)[CH](NC(C(F)(F)C)=O)C)=C4)=C2